Energy News / Shareholders Foundation, Inc.

NASDAQ: SRPT Investor Notice: Lawsuit Alleges False and Misleading Statements by Sarepta Therapeutics, Inc.

Via: ReleaseWire

Updated 11:00 AM CST, Mon, November 04,2019

A lawsuit was filed on behalf of investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares over alleged securities laws violations.

San Diego, CA -- (SBWIRE) -- 11/04/2019 -- An investor, who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT), filed a lawsuit over alleged violations of Federal Securities Laws by Sarepta Therapeutics, Inc.

Investors who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have certain options and for certain investors are short and strict deadlines running. Deadline: October 29, 2019. NASDAQ: SRPT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Cambridge, MA based Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. On August 19, 2019, Sarepta Therapeutics, Inc. announced receipt of a Complete Response Letter ("CRL") from the U.S. Food & Drug Administration regarding the Company's New Drug Application seeking accelerated approval of golodirsen injection for the treatment of Duchenne muscular dystrophy. Sarepta disclosed that "[t]he CRL generally cites two concerns: the risk of infections related to intravenous infusion ports and renal toxicity seen in pre-clinical models of golodirsen and observed following administration of other antisense oligonucleotides." Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) declined to as low as $90.24 per share on August 22, 2019.

The plaintiff claims that between September 6, 2017 and August 19, 2019, the Defendants made false and/or misleading statements and/or failed to disclose that golodirsen posed significant safety risks to patients, that consequently, the NDA package for golodirsen's accelerated approval was unlikely to receive FDA approval, and that as a result, Sarepta's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaq-srpt-investor-notice-lawsuit-alleges-false-and-misleading-statements-by-sarepta-therapeutics-inc-1263990.htm

Media Relations Contact
Michael Daniels
1-858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com